论文部分内容阅读
目的观察黄芪注射液在小儿支原体肺炎中的临床疗效及安全性。方法选取2009年7月至2011年7月本院收治的68例支原体肺炎患儿为研究对象,将其随机地分为对照组和实验组,对照组34例给予常规西药治疗,实验组34例在常规西药治疗的基础上加用黄芪注射液治疗,对比两组患儿临床疗效及并发症发生率。结果实验组总有效率为97%,并发症发生率为8.9%;对照组总有效率为88.2%,并发症发生率为20.6%。两组对比差异具有统计学意义(P<0.05)。结论黄芪注射液治疗小儿支原体肺炎效果显著,安全性较高,因此,临床应用价值较高,值得推广和应用。
Objective To observe the clinical efficacy and safety of astragalus injection in children with mycoplasma pneumonia. Methods Sixty-eight children with mycoplasma pneumonia admitted in our hospital from July 2009 to July 2011 were selected as study subjects, randomly divided into control group and experimental group, 34 cases in control group received conventional western medicine, and 34 cases in experimental group On the basis of conventional Western medicine plus astragalus injection treatment, the clinical efficacy and complication rates were compared between the two groups. Results In the experimental group, the total effective rate was 97% and the complication rate was 8.9%. The total effective rate was 88.2% in the control group and the complication rate was 20.6%. The difference between the two groups was statistically significant (P <0.05). Conclusion Astragalus injection treatment of children with mycoplasma pneumonia significant effect, high safety, therefore, the clinical application of high value, it is worth promoting and application.